• Xiaoyan Zhang, Shujuan Ma, and Baocai Fu.
• Department of Respiratory Medicine, Changyi People's Hospital.
• Medicine (Baltimore). 2021 Apr 16; 100 (15): e25491e25491.

BackgroundTo the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD). Therefore, in order to provide new evidence-based medical evidence for clinical treatment, we undertook a systematic review and meta-analysis to assess the effectiveness and safety of bisoprolol combined with trimetazidine on CHF patients with COPD.MethodsSeven electronic databases including Web of Science, Embase, PubMed, Wanfang Data, Scopus, Science Direct, Cochrane Library will be searched in April 2021 by 2 independent reviewers. For search on PubMed, the following search terms will be used: "trimetazidine, bisoprolol, chronic heart failure, chronic obstructive pulmonary disease." In order to achieve a consistency of extracted items, the data extractors will extract data from a sample of eligible studies. The outcomes include all-cause mortality and hospitalization for cardiac or/and respiratory causes; left ventricular structure and function; and functional scores. Review Manager software (v 5.4; Cochrane Collaboration) will be used for the meta-analysis. Two independent reviewers will assess the risk of bias of the included studies at study level. Any disagreements will be discussed and resolved in discussion with a third reviewer.ResultsThe results of our review will be reported strictly following the PRISMA criteria.ConclusionsThe review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.Osf Registration Number10.17605/OSF.IO/ZWPRB.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

36 keywords...

hide…